Gastroenterology Research and Practice / 2019 / Article / Tab 1

Research Article

Quantitative Analysis of HER2 Amplification by Droplet Digital PCR in the Follow-Up of Gastric Cancer Patients Being Treated with Trastuzumab after Surgery

Table 1

Clinicopathological characteristics of all patients.

Patient IDAgeGenderTumor locationTumor size (cm)DifferentiationLymph node metastasisDistant metastasisStageTNMTreatment

153FemaleAntrum4PoorPositiveLiverIVT4aNxM1FOLFOX+trastuzumab
236MaleAntrum4.5PoorPositivePeritoneumIVT4N1M1FOLFOX+trastuzumab
364FemaleCardia4ModeratePositiveLiverIVT4NxM1FOLFOX+trastuzumab
470FemaleCardia5PoorPositiveLiverIVT4bNxM1FOLFOX+trastuzumab
571MaleBody6.5PoorPositiveLiverIVT4N1M1FOLFOX+trastuzumab
665MaleBody5.5ModeratePositivePeritoneumIVT4bN1M1FOLFOX+trastuzumab
779MaleAntrum4ModeratePositiveLiverIVT4N1M1FOLFOX+trastuzumab
872MaleAntrum5PoorPositiveLiverIVT4N1M1FOLFOX+trastuzumab
956MaleCardia4ModeratePositivePeritoneumIVT4bN1M1FOLFOX+trastuzumab
1059FemaleCardia5ModeratePositiveLiverIVT4aNxM1FOLFOX+trastuzumab
1164FemaleBody4PoorPositivePeritoneumIVT4N1M1FOLFOX+trastuzumab
1272MaleAntrum4.5ModeratePositiveLiverIVT4N1M1FOLFOX+trastuzumab

FOLFOX = oxaliplatin (L-OHP)+calcium folinate (CF)+5-fluorouracil (5-Fu).

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.